Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial - Concepedia

Concepedia

Publication | Closed Access

Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial

144

Citations

21

References

2004

Year

Monia Marchetti, Giovanni Barosi, Francesca Balestri, Gianluca Viarengo, S Gentili, Sara Barulli, Jean-Loup Demory, Fiorella Ilariucci, Antonio Volpe, Dominique Bordessoule,

Journal of Clinical Oncology

Abstract

Low-dose thalidomide displays an acceptable toxicity profile and provides an objective and subjective advantage to a relevant portion of MMM patients.

References

	Year	Citations

Page 1